Impact of comorbidities on outcomes in patients with advanced head and neck cancer undergoing immunotherapy

To explore the impact of pre-existing comorbidities on immunotherapy response, overall and progression-free survival, and immune-related adverse events (irAEs) of patients with advanced head and neck cancer (HNC) treated with immunotherapy. Ninety-three patients treated with immunotherapy were ident...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2023-11, Vol.45 (11), p.2789-2797
Main Authors: Guller, Meytal, Cooper, Dylan J, Alkhatib, Hosam, Suru, Aditya, Blancaflor, Angelo, Maroun, Christopher A, Tham, Tristan, Allen, Hailey, Mazzara, Eden, Thomas, Jerin, Amin, Neha, Wu, Evan, Eisele, David W, Fakhry, Carole, Pardoll, Drew, Seiwert, Tanguy Y, Zhu, Gangcai, Mandal, Rajarsi
Format: Article
Language:English
Subjects:
Comorbidity
Decision making
Head & neck cancer
Head and Neck Neoplasms - therapy
Humans
Immunotherapy
Immunotherapy - adverse effects
Prognosis
Progression-Free Survival
Retrospective Studies
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To explore the impact of pre-existing comorbidities on immunotherapy response, overall and progression-free survival, and immune-related adverse events (irAEs) of patients with advanced head and neck cancer (HNC) treated with immunotherapy. Ninety-three patients treated with immunotherapy were identified and stratified into comorbidity absent or present (CCI 
ISSN:1043-3074
1097-0347
1097-0347
DOI:10.1002/hed.27502